Meeting
2019 Genitourinary Cancers Symposium
Phase II trial of nivolumab (nivo) plus ipilimumab (ipi) in patients with SMARCB1-deficient kidney malignancies.
Authors
Pavlos Msaouel
University of Texas MD Anderson Cancer Center, Houston, TX
Pavlos Msaouel , Rebecca Slack-Tidwell , Nizar M. Tannir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03274258
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS677)
DOI
10.1200/JCO.2019.37.7_suppl.TPS677
Abstract #
TPS677
Poster Bd #
K8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
First Author: Rohit K. Jain
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma.
First Author: Patrick Walsh McGarrah
Poster
2023 ASCO Annual Meeting
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma.
First Author: Julie L. Koenig
Poster
2023 ASCO Annual Meeting
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.
First Author: Julie L. Koenig